They purchased the shares on Sept 25th. Unfortunately we probably will not get too much of a bump because they didn't buy these on the open market. Often these firms will accumulate at a specified price with the trading firms in an "across the board" or "off trading floor" trade.
But man did they accumulate a TON of shares!
The way that I read the 13G is that the same company accumulated as 2 separate entities of 5.4% and 3.3% for a total of 8.7% of the company. Along with Visium gaining 9.4% earlier last week, that is nearing 20% increase in institutional ownership.
These companies are seeing the value of SNSS not only with Vosaroxin but also as a subsidiary to a large pharma needing to add the patents and phase III drug into their pipeline.
I anticipate a modest decline for a period of time until either we hit BO rumor or announcement from Biogen Idec or Millenium on progression of Raf Kinase Inhib studies.
It has been wonderful ride so far. I think we still have a lot of potential left in this company.